Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER: Preoperative Atezolizumab in Local Head and Neck Squamous Cell Carcinoma
NCT04939480Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Oct 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Universitätsmedizin Essen. Primary endpoints: Effect of atezolizumab on tumor-infiltrating immune cells in resectable SCCHN at 4 weeks and Feasibility of preoperative short time immunotherapy at 3 weeks. Started Oct 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04939480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939480.